Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.
The iShares Biotechnology ETF (IBB) increased 0.3%.
In corporate news, Fate Therapeutics (FATE) shares rose nearly 6% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.